Vor Biopharma Inc. (VOR)
NASDAQ: VOR · IEX Real-Time Price · USD
0.923
+0.006 (0.69%)
At close: Jul 19, 2024, 4:00 PM
0.990
+0.067 (7.21%)
Pre-market: Jul 22, 2024, 7:00 AM EDT
Vor Biopharma Stock Forecast
VOR's stock price has decreased by -71.41% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Vor Biopharma stock have an average target of 12.5, with a low estimate of 10 and a high estimate of 17.5. The average target predicts an increase of 1,253.84% from the current stock price of 0.92.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 13, 2024.
Analyst Ratings
The average analyst rating for Vor Biopharma stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
Buy | 4 | 4 | 3 | 3 | 3 | 3 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 7 | 7 | 6 | 6 | 6 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JMP Securities | JMP Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +1,199.69% | May 13, 2024 |
Oppenheimer | Oppenheimer | Buy Reiterates $15 → $10 | Buy | Reiterates | $15 → $10 | +983.07% | May 13, 2024 |
Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +1,091.38% | May 10, 2024 |
Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +1,091.38% | Apr 23, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +1,199.69% | Mar 22, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.62
from -1.75
EPS Next Year
-1.38
from -1.62
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | n/a | 102.2M | 200.1M |
Avg | n/a | n/a | n/a | 41.3M | 131.9M |
Low | n/a | n/a | n/a | 7.4M | 76.8M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 384.2% |
Avg | - | - | - | - | 219.2% |
Low | - | - | - | - | 85.9% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.18 | -0.82 | -0.69 | -0.32 | 0.75 |
Avg | -1.62 | -1.38 | -1.21 | -1.05 | -0.54 |
Low | -1.73 | -1.76 | -1.51 | -1.55 | -1.24 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.